Validation of Multiplex Serology for human hepatitis viruses B and C, human T-lymphotropic virus 1 and Toxoplasma gondii.
Antibodies, Viral
/ blood
Antigens
/ immunology
Antigens, Protozoan
/ immunology
Antigens, Viral
/ immunology
HTLV-I Infections
/ blood
Hepacivirus
/ immunology
Hepatitis B
/ blood
Hepatitis B virus
/ immunology
Hepatitis C
/ blood
High-Throughput Screening Assays
Human T-lymphotropic virus 1
/ immunology
Humans
Seroepidemiologic Studies
Serologic Tests
/ methods
Toxoplasma
/ immunology
Toxoplasmosis
/ blood
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2019
2019
Historique:
received:
27
09
2018
accepted:
21
12
2018
entrez:
8
1
2019
pubmed:
8
1
2019
medline:
19
10
2019
Statut:
epublish
Résumé
Multiplex Serology is a high-throughput technology developed to simultaneously measure specific serum antibodies against multiple pathogens in one reaction vessel. Serological assays for hepatitis B (HBV) and C (HCV) viruses, human T-lymphotropic virus 1 (HTLV-1) and the protozoan parasite Toxoplasma gondii (T. gondii) were developed and validated against established reference assays. For each pathogen, between 3 and 5 specific antigens were recombinantly expressed as GST-tag fusion proteins in Escherichia coli and tested in Monoplex Serology, i.e. assays restricted to the antigens from one particular pathogen. For each of the four pathogen-specific Monoplex assays, overall seropositivity was defined using two pathogen-specific antigens. In the case of HBV Monoplex Serology, the detection of past natural HBV infection was validated based on two independent reference panels resulting in sensitivities of 92.3% and 93.0%, and specificities of 100% in both panels. Validation of HCV and HTLV-1 Monoplex Serology resulted in sensitivities of 98.0% and 95.0%, and specificities of 96.2% and 100.0%, respectively. The Monoplex Serology assay for T. gondii was validated with a sensitivity of 91.2% and specificity of 92.0%. The developed Monoplex Serology assays largely retained their characteristics when they were included in a multiplex panel (i.e. Multiplex Serology), containing additional antigens from a broad range of other pathogens. Thus HBV, HCV, HTLV-1 and T. gondii Monoplex Serology assays can efficiently be incorporated into Multiplex Serology panels tailored for application in seroepidemiological studies.
Identifiants
pubmed: 30615688
doi: 10.1371/journal.pone.0210407
pii: PONE-D-18-28149
pmc: PMC6322760
doi:
Substances chimiques
Antibodies, Viral
0
Antigens
0
Antigens, Protozoan
0
Antigens, Viral
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Validation Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0210407Subventions
Organisme : Wellcome Trust
ID : 109965/Z/15/Z
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 106289/Z/14/Z
Pays : United Kingdom
Organisme : Department of Health
Pays : United Kingdom
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
J Virol. 2000 Mar;74(5):2193-202
pubmed: 10666249
J Gen Virol. 2009 Aug;90(Pt 8):1806-1811
pubmed: 19423550
Clin Chem. 2005 Oct;51(10):1845-53
pubmed: 16099939
Hepatology. 2018 Sep;68(3):827-838
pubmed: 29377196
Exp Parasitol. 2008 Jul;119(3):373-8
pubmed: 18457835
Antiviral Res. 2017 Jan;137:41-48
pubmed: 27840202
Am J Epidemiol. 2016 Jan 1;183(1):61-9
pubmed: 26667254
World J Hepatol. 2017 Nov 28;9(33):1239-1252
pubmed: 29312527
Exp Parasitol. 2006 Sep;114(1):62-5
pubmed: 16545806
Exp Parasitol. 2013 Dec;135(4):685-9
pubmed: 24140597
Infect Agent Cancer. 2017 Feb 2;12:9
pubmed: 28168002
Cancer Epidemiol Biomarkers Prev. 2012 Sep;21(9):1599-601
pubmed: 22736792
N Engl J Med. 1980 Oct 9;303(15):833-41
pubmed: 6997738
Lancet. 2015 Oct 17;386(10003):1546-55
pubmed: 26231459
J Hepatol. 2014 Nov;61(1 Suppl):S45-57
pubmed: 25086286
Handb Clin Neurol. 2013;114:125-45
pubmed: 23829904
Hepatology. 1999 Mar;29(3):908-14
pubmed: 10051497
Lancet. 1986 May 3;1(8488):1031-2
pubmed: 2871307
J Acquir Immune Defic Syndr (1988). 1990;3(11):1096-101
pubmed: 2213510
Int J Cancer. 1997 Apr 10;71(2):196-202
pubmed: 9139842
Cancer Epidemiol Biomarkers Prev. 2015 Sep;24(9):1360-5
pubmed: 26169147
Annu Rev Immunol. 1997;15:15-37
pubmed: 9143680
Am J Epidemiol. 2016 Apr 1;183(7):671-9
pubmed: 26968942
J Chiropr Med. 2016 Jun;15(2):155-63
pubmed: 27330520
J Clin Microbiol. 2004 Nov;42(11):5133-8
pubmed: 15528706
Proc Biol Sci. 1993 Aug 23;253(1337):197-201
pubmed: 8397416
Clin Exp Hepatol. 2017 Jun;3(2):35-46
pubmed: 28856289
Vaccine. 2010 Feb 17;28(7):1803-7
pubmed: 20018269
J Infect Dis. 1985 Apr;151(4):599-603
pubmed: 3973412
Curr Opin Virol. 2017 Apr;23:113-119
pubmed: 28550816
Parasitol Res. 2018 Oct;117(10):3059-3065
pubmed: 30109417
Lancet Oncol. 2009 Apr;10(4):321-2
pubmed: 19350698
Int J Parasitol. 2009 Oct;39(12):1385-94
pubmed: 19433092
J Immunol. 2011 Jul 1;187(1):361-71
pubmed: 21646298
Int J Cancer. 2018 Aug 1;143(3):570-579
pubmed: 29574937
J Gen Virol. 2010 Feb;91(Pt 2):483-92
pubmed: 19812261
BMJ. 2000 Mar 4;320(7235):611-2
pubmed: 10698878
J Immunol Methods. 2001 Jul 1;253(1-2):153-62
pubmed: 11384677
Int J Cancer. 2018 Jun 15;142(12):2471-2477
pubmed: 29388206
Helicobacter. 2009 Dec;14(6):525-35
pubmed: 19889070
Gut. 1993;34(2 Suppl):S17-9
pubmed: 8314488
Cold Spring Harb Perspect Med. 2014 Oct 30;4(12):a024935
pubmed: 25359547
Lancet. 2003 Dec 20;362(9401):2095-100
pubmed: 14697814
Fam Med. 2005 May;37(5):360-3
pubmed: 15883903
Emerg Infect Dis. 2003 Nov;9(11):1375-80
pubmed: 14725265
J Gen Virol. 1999 Mar;80 ( Pt 3):727-738
pubmed: 10092013
Scand J Immunol. 1994 Aug;40(2):171-80
pubmed: 8047838
Infection. 2018 Jun;46(3):303-315
pubmed: 29330674
N Engl J Med. 2004 Mar 11;350(11):1118-29
pubmed: 15014185
BMJ. 2014 Apr 17;348:g2522
pubmed: 24742733
Lancet. 1997 Jul 19;350(9072):173-7
pubmed: 9250185
Parasitology. 1988 Aug;97 ( Pt 1):1-10
pubmed: 3174230